Multicentric, Randomized, Double-Blind Study Versus Placebo, With Two Parallel Groups Treated to Evaluate the Efficacy and the Tolerance of Riluzole in Children and Young Adults (6 to 20 Years of Age) With SMA. (Type II and Type III).

Trial Profile

Multicentric, Randomized, Double-Blind Study Versus Placebo, With Two Parallel Groups Treated to Evaluate the Efficacy and the Tolerance of Riluzole in Children and Young Adults (6 to 20 Years of Age) With SMA. (Type II and Type III).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs Riluzole (Primary)
  • Indications Spinal muscular atrophy
  • Focus Therapeutic Use
  • Acronyms ASIRI
  • Most Recent Events

    • 21 Sep 2011 Planned end date changed from 1 Jun 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 07 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top